Skip to main content
SpringerLink
Log in

How effective are antacids in the treatment of gastric ulcer?

Was leisten Antacida beim Ulcus ventriculi?

  • Chapter
Book cover Therapeutische Möglichkeiten bei Erkrankungen des oberen Gastrointestinaltraktes: Antacida im Blickpunkt

  • 6 Accesses

Abstract

Antacids are effective therapeutic agents in peptic ulcers. The efficacy of antacids cannot be explained by the acid neutralization capacity only because very low dosages with a daily neutralization capacity of 100-200 ml are already effective.

Other factors are also discussed which may play an active role in ulcer-disease, such as bile acids, Helicobacter pylori, PAF and Crack, as well as how antacids may influence these acid-independant factors.

Zusammenfassung

Ulzera können mit Antacida wirksam behandelt werden. Die Effektivität der Antacida läßt sich nicht allein durch ihre Säureneutralisationskapazität erklären, da schon sehr niedrige Dosierungen mit einer Neutralisationskapazität von 100=200 mmol/Tag Ulzera zur Abheilung bringen. Diskutiert wird auch, inwieweit säureunabhängige Faktoren wie Gallensäuren, der plättchenaktivierende Faktor, exogene Noxen (Crack) und Helicobacter pylori an der Genese des Ulcus ventriculi beteiligt sind und welchen Einfluß Antacida auf diese aggressiven Faktoren haben.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literaturverzeichnis

  1. Abramson DL, Gertler JP, Lewis T, Gral JG. Crack-related perforated gastropyloric ulcer. J Clin Gastroenterol 1991; 13: 17–19.

    Article  CAS  PubMed  Google Scholar 

  2. Aceti A, Celestino D, Caferro M, Casale V, Citarda F, Conti EM et al. Basophilbound and serum immunoglobulin E directed against Helicobacter pylori in patients with chronic gastritis. Gastroenterology 1991; 101: 131–137.

    CAS  PubMed  Google Scholar 

  3. Bezuidenhout DJJ, Perold JG, Adams G. A comparison of 4-week peptic ulcer healing rates following treatment with antacids and ranitidine. S Afr Med J 1984; 65: 1007–1009.

    CAS  PubMed  Google Scholar 

  4. Black RB, Hole D Rhodes Jw. Bile damage to the gastric mucosal barrier: the influence of pH and bile acid concentration. Gastroenterology 1971; 61: 178–184.

    CAS  PubMed  Google Scholar 

  5. Blum AL. Stellung der Antazida in der modernen Ulkustherapie. Dtsch Med Wochenschr 1985; 110: 3–7.

    Article  CAS  PubMed  Google Scholar 

  6. Bosseckert H, Fuckel R, Winnefeld K. Gallegehalt im Magensaft bei Magenerkrankungen. Noch nicht veröffentlicht.

    Google Scholar 

  7. Brackmann H-P. Physiologisch-logische Wirkprinzipien in der Ulkustherapie. Therapiewoche 1985; 35: 4007–4023.

    Google Scholar 

  8. Brzozowski T, Majka J, Garlicki J, Drozdowicz D, Konturek S. Role of polyamines and prostaglandins in gastroprotective action of epidermal growth factor against ethanol injury. J Clin Gastroenterol 1991; 13 (Suppl 1): 98–100.

    Article  Google Scholar 

  9. Bugnoli M, Armellini D, Figura N, Rossolini A. The 130 kDa vacuolizing cytotoxinassociated protein is a component of cytotoxic Helicobacter pylori organisms. Ital J Gastroenterol 1991; 23 (Suppl 2): 37.

    Google Scholar 

  10. Butler ML Gersh H. Antacid vs placebo in hospitalized gastric ulcer patients: A controlled therapeutic study. Am J Dig Dis 1975; 20: 803–807.

    Article  CAS  PubMed  Google Scholar 

  11. Caspary WF, Graf S. Bindung von Gallensäuren an Antazida. Dtsch Med Wochenschr 1978; 103: 825–827.

    Article  CAS  PubMed  Google Scholar 

  12. Chan WY, Hui PK, Chan JKC, Cheung PSY, NG CS, Sham CH. Epithelial damage by Helicobacter pylori in gastric ulcers. Histopathology 1991; 19: 47–53.

    Article  CAS  PubMed  Google Scholar 

  13. Clemencon GH. Der duodenogastrische Reflux—endoskopische Diagnose. Akt Gastrol 1979; 8: 461–470.

    Google Scholar 

  14. Crabtree JE, Taylor JD, Wyatt JI, Shallcross TM, Heatley RV, Tompkins DS et al. Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulcers and gastric pathology. Ital J Gastroenterol 1991; 23 (Suppl 2): 51.

    Google Scholar 

  15. Davenport HW. Destruction of the gastric mucosal barrier by detergents and urea. Gastroenterology 1968; 54: 175–181.

    CAS  PubMed  Google Scholar 

  16. Daw MA, Keane CT, Moore RO, Morain CO. Phospholipase C activity: new pathogenicity marker for Helicobacter pylori. Ital J Gastroenterol 1991; 23 (Suppl 2): 37–38.

    Google Scholar 

  17. Denizot Y, Sobhani J, Rambaud JC, Lewin M, Thomas Y, Benveniste J. Paf-acether synthesis by Helicobacter pylori. Gut 1990; 31: 1242–1245.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Eastwood GL. Effect of pH on bile salt injury to mouse gastric mucosa. A light- and electron-microscopic study. Gastroenterology 1975; 68: 1456–1465.

    CAS  PubMed  Google Scholar 

  19. Englert E JR, Freston JW, Graham DY et al. Cimetidine, antacid and hospitalization in the treatment of benign gastric ulcer. A multicenter double-blind study. Gastroenterology 1978; 74: 416–425.

    PubMed  Google Scholar 

  20. Flemstrom G, Turnberg LA. Gastroduodenal defence mechanisms. Clin Gastroenterol 1984; 13: 327–354.

    CAS  PubMed  Google Scholar 

  21. Fordtran JS, Stephan G, Morawski BA, Richardson CT. In vivo and in vitro evaluation of liquid antacids. N Engl J Med 1973; 288: 923–928.

    Article  CAS  PubMed  Google Scholar 

  22. Gough KR. Klinische Erfahrungen mit der Langzeittherapie: Sicherheit und Nebenwirkungen. Res Clin Forum 1989; 10: 85–91.

    Google Scholar 

  23. Hazell SC. Urease and Catalase as virulence factor of Helicobacter pylori. In: Menge H, Gregor M, Tytgat GNJ, Marshall BJ, McNulty CAM (eds.). Helicobacter pylori 1990. Springer 1991: 3–12.

    Chapter  Google Scholar 

  24. Hollander D, Harlom J. Antacids vs placebo in peptic ulcer therapy. J Am Med Wom Assoc 1973; 226: 1181–1183.

    Article  CAS  Google Scholar 

  25. Holzer P, Pabst MA, Lippe JT. Intragastric Capsaicin protects against aspirin-induced lesion formations and bleeding in the rat gastric mucosa. Gastroenterology 1989; 96: 1425–1433.

    CAS  PubMed  Google Scholar 

  26. Isenberg JI, Peterson WL, Elashoff JD et al. Healing of benign gastric ulcer with lowdose antacid or cimetidine. A double-blind, randomized, placebo-controlled trial. N Eng! J Med 1983; 308: 1319–1324.

    Article  CAS  Google Scholar 

  27. Ivey KJ, Denbesten L, Clifton JA. Effect of bile salts On ionic movement across the human gastric mucosa. Gastroenterology 1970; 59: 683–690.

    CAS  PubMed  Google Scholar 

  28. Ivey KJ. Gastric mucosal barrier. Gastroenterology 1971; 61: 247–257.

    CAS  PubMed  Google Scholar 

  29. Kurose I, Suetmatso M, Miura S, Suzuki M, Nagata H, Morishita T et al. Involvement of superoxide anion and platelet — activating factor in increased tissue-type plasminogen activator during rat gastric microvascular damages. Thromb Res 1991; 62: 241–248.

    Article  CAS  PubMed  Google Scholar 

  30. Kurtz W, Güldütuna S, Leuschner U. Einfluß von pH und Antazidummenge auf die Gallensäuren-Bindung in quasinatürlichem Refluxmilieu. Z Gastroenterol 1991; 29: 237–241.

    CAS  PubMed  Google Scholar 

  31. Lanza FL, Sibley CM. Role of antacids in the management of disorders of the upper gastrointestinal tract. Rev Clin Exp 1975–1985.

    Google Scholar 

  32. Lingwood CA, Law H, Pellizzari A, Sherman P, Drumm B. Gastric glycerolipid as a receptor of Campylobacter pylori. Lancet 1989; II: 238–241.

    Article  Google Scholar 

  33. Littman A, Welch R, Fruin RC, Aronson AR. Controlled trials of aluminium hydroxyde gels for peptic ulcer. Gastroenterology 1977; 73: 6–10.

    CAS  PubMed  Google Scholar 

  34. Lopez Lavid C, Sanz JC, Martin E, Castanos R, Junenez J, Lopez-brea M. Helicobacter pylori: Biotypes and correlation with antimicrobial susceptibility. Rev Esp Enferm Apar Dig 1990; 78 (Suppl 1): 94.

    Google Scholar 

  35. Miederer SE, Mayershofer R, LÖFfler A. Magaldrat (100 mmol/d) gegen Ranitidin (300 mg/d). Med Klin 1986; 81: 162–165.

    CAS  Google Scholar 

  36. Miyake T, Ariyoshi J, Suzaki T et al. Endoscopic evaluation of the effect of sucralfate therapy and other clinical parameters on the recurrence rate of gastric ulcers. Dig Dis Sci 1980;25: 1–7.

    Article  CAS  PubMed  Google Scholar 

  37. Mooney C, Keenan J, Munster D, Wilson J, Allardyce R, Bagshaw B et al. Neutrophil activation by Helicobacter pylori. Gut 1991; 32: 833–837.

    Article  Google Scholar 

  38. Morgan AG, Pacsoo C, Mcadam Waf. Maintenance therapy: A two-year comparison between Caved-S and cimetidine treatment in the prevention of symptomatic gastric ulcer recurrence. Gut 1985; 26: 599–602.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Nagy L, Mozsik GY, Vincze A, Süto G, Hunyady B, Rinfel J et al. Effects of a novel hungarian antacid combining Al and Mg (Tisacid) on mucosal prostaglandin generation and oxygen free radicals in normal rat. Drugs Exp Clin Res 1990; 16: 197–203.

    CAS  PubMed  Google Scholar 

  40. Negrini R, Lisato L, Zanella J, Cavazzini L, Gullini S, Villanacci V et al. Helicobacter pylori infection induces antibodies cross-reacting with human gastric mucosa. Gastroenterology 1991; 101: 437–445.

    CAS  PubMed  Google Scholar 

  41. Pace F, Broker HJ, Domschke W et al. Treatment of gastric ulcer with low-dose antacid gel and cimetidine: A multi-centre double-blind trial. Dtsch Med Wochenschr 1985; 110: 283–287.

    Article  CAS  PubMed  Google Scholar 

  42. Pace F, Bröker H-J, Caspary W, Domschke W, Feurle G, Fimmel CJ et al. Therapie des Ulcus ventriculi mit niedrig dosiertem Antacidumgel und Cimetidin. Dtsch Med Wochenschr 1985; 110: 283–287.

    Article  CAS  PubMed  Google Scholar 

  43. Rio MC, Chenard MP, Wolf C, Marcellin L, Tomasetto C, Lathe R et al. Induction of pS2 and USP Genes as markers of mucosal ulceration of the digestive tract. Gastroenterology 1991; 100: 375–379.

    CAS  PubMed  Google Scholar 

  44. Sherbaniuk RW, Wensel RH, Bailey RJ et al. Comparative study of cimetidine and Mylanta-II in the 6-week treatment of gastric ulcer. J Clin Gastroenterol 1985; 7: 211–215.

    Article  CAS  PubMed  Google Scholar 

  45. Sipponen P, SeppäLä K, äärginen M, Helske T, Kettunen P. Chronic gastritis and gastroduodenal ulcer: a case control study on risk of coexisting duodenal or gastric ulcer in patients with gastritis. Gut 1989; 30: 922–929.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Szelenyi J. Mukosabarriere — Schutz durch Prostaglandine. Z Allg Med 1984; 60: 1306–1314.

    Google Scholar 

  47. Vergin H, Kori-Lindner C. Rutative mechanisms of cytoprotective effect of certain antacids and sucralfate. Dig Dis Sci 1990; 35: 1320–1327.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin, Friedrich-Schiller-Universität, Jena, Deutschland

    H. Bosseckert

Authors
  1. H. Bosseckert
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung für Gastroenterologie, Inselspital Bern, CH-3010, Bern, Schweiz

    F. Halter

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer Fachmedien Wiesbaden

About this chapter

Cite this chapter

Bosseckert, H. (1992). How effective are antacids in the treatment of gastric ulcer?. In: Halter, F. (eds) Therapeutische Möglichkeiten bei Erkrankungen des oberen Gastrointestinaltraktes: Antacida im Blickpunkt. Vieweg+Teubner Verlag, Wiesbaden. https://doi.org/10.1007/978-3-663-05262-3_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-663-05262-3_11

  • Publisher Name: Vieweg+Teubner Verlag, Wiesbaden

  • Print ISBN: 978-3-663-05263-0

  • Online ISBN: 978-3-663-05262-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation